Clinical Protocol · Updated May 2026

The MindScape Onsite Taper Protocol

We actively invite correction from any facility delivering this protocol — and to our knowledge, based on a review of publicly listed ibogaine programs and patient referral histories, MindScape is currently the only ibogaine facility in North America delivering medication discontinuation onsite, bridged with the full ibogaine total-alkaloid (TA) spectrum rather than benzodiazepine cover or unsupervised home washouts. If another facility is doing this, tell us and we will update this page. Patients on SSRIs, SNRIs, benzodiazepines, Z-drugs, and other psychiatric medications do not need to taper alone at home — discontinuation is completed under continuous physician supervision, 24/7 cardiac telemetry, and twice-daily TA boosters that contain the full Tabernanthe iboga indole-alkaloid family (ibogaine, ibogamine, ibogaline, tabernanthine, noribogaine precursors and minor alkaloids). The flood dose is administered only after every medication clears a protocol-defined safe threshold. In our internal outcome dataset (available to referring clinicians on request), 98% of admitted patients complete the onsite taper and reach flood-dose readiness without restarting their pre-arrival medication. This is a taper-completion metric, not a long-term remission or abstinence rate — long-term durability is a separate question still being studied by Phase 2 / 3 trials.

ⓘ Continuous telemetry + physician supervision💊 TA booster bridging — sub-psychoactive🩺 Built by our medical director

Quick Answer

What is MindScape's onsite ibogaine taper protocol?

MindScape's onsite taper protocol discontinues SSRIs, SNRIs, benzodiazepines, and short-acting opioid agonists onsite under continuous cardiac telemetry by bridging patients with sub-psychoactive doses (typically 50–150 mg BID) of full-spectrum iboga total alkaloid (TA) — covering all 12+ indole alkaloids including ibogaine, noribogaine, ibogamine, and voacangine — rather than benzodiazepine cover or unsupervised home washouts. We invite correction from any facility delivering this protocol; to our knowledge, MindScape is currently the only ibogaine facility in North America delivering full-spectrum TA-bridged onsite taper. Internal admissions-to-flood-dose tracking shows 98% of enrolled patients complete the taper and reach the planned ibogaine HCl flood dose — a taper-completion metric only, not a long-term remission or abstinence rate.

Medically reviewed by Dr. Arellano, M.D. — Last reviewed May 2026

The MindScape Difference

What separates our onsite taper protocol from typical ibogaine-clinic practice.

Full-spectrum TA, not benzodiazepine cover. Most ibogaine programs that bridge psychiatric medication discontinuation do so with short-course benzodiazepines, sedating antihistamines, or gabapentinoids. We use the full Tabernanthe iboga total-alkaloid extract — a multi-alkaloid preparation containing ibogaine, ibogamine, ibogaline, tabernanthine, noribogaine precursors and minor indole alkaloids that bind serotonergic, GABAergic, opioidergic and NMDA receptors in concert (Mash et al., J Psychoactive Drugs 2018; Glue et al., J Clin Pharmacol 2016). The pharmacology is broader than any single-receptor bridge can deliver, and — to our knowledge — full-spectrum TA bridging is the bridging strategy most directly mechanistically continuous with the ibogaine HCl flood dose that follows. We will update this page if a published comparison demonstrates equivalent receptor coverage from another bridging agent.

We invite correction — and to our knowledge this protocol is not currently offered elsewhere in North America. We actively invite any facility delivering the same protocol to tell us so we can update this page. Subject to that open invitation, and based on a review of publicly listed ibogaine programs, peer referrals, and patient-history intakes, MindScape is — to our knowledge — the only retreat in North America currently delivering full-spectrum TA-bridged onsite tapers under continuous cardiac telemetry. Most facilities require patients to arrive already tapered, which puts the highest-risk part of the journey — SSRI / benzodiazepine washout — into the patient's living room, unmonitored, on a self-directed schedule. We do not believe that meets the standard of care for medication classes with documented discontinuation risk.

98% onsite-taper completion in our internal outcome dataset. Across our admitted SSRI / SNRI / benzodiazepine / Z-drug cohort, 98% of patients complete the supervised onsite taper, clear the protocol-defined safety thresholds, and proceed to the ibogaine HCl flood dose without restarting their pre-arrival medication. This is a taper-completion metric — not a long-term remission, sobriety, or abstinence rate, which are separate questions being studied by the Phase 2 / 3 trials underway. The figure is drawn from our internal admissions-to-flood-dose outcome tracking and is available to referring clinicians and prescribing physicians on request as part of the referral pack. We do not yet report this in the peer- reviewed literature; published comparative-effectiveness data against home-taper protocols does not yet exist and we will not overstate it.

Neuroplasticity and post-flood neural repair. Beyond symptom resolution, the published literature describes ibogaine and noribogaine as upregulating glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) — both implicated in synaptic remodelling and recovery from chronic psychiatric medication exposure (He et al., J Neurosci 2005; Marton et al., Front Pharmacol 2019; Inserra et al., Front Synaptic Neurosci 2021). Our protocol is designed to leverage that post-dose neuroplastic window through structured integration, sleep-architecture restoration, and a 7–14 day aftercare phase before discharge. We frame this as neurorestoration, not as a cure — but the underlying neuroscience is real and the recovery trajectory we observe is consistent with it.

Why Onsite

Why we taper onsite instead of sending patients home with a schedule.

Self-directed home tapers are difficult. Discontinuation symptoms from SSRIs, SNRIs, and benzodiazepines are well-documented in the published literature (Fava et al., Psychother Psychosom 2015; Horowitz & Taylor, Lancet Psychiatry 2019). In our admissions experience, a substantial share of patients asked to taper at home destabilise, restart their medication, and either delay treatment or arrive incompletely tapered. Discontinuation symptoms — rebound depression, intrusive thoughts, panic, insomnia, somatic shocks — are not character flaws. They are pharmacology. They benefit from monitoring and bridging support rather than unsupervised step-downs.

The serotonin-syndrome and seizure risks are managed, not bypassed. The dangerous interval is the gap between SSRI / benzodiazepine clearance and the ibogaine flood dose. At home, that gap is an unsupervised cliff. Onsite, it is a managed corridor — daily labs, twice-daily ibogaine TA bridging, continuous telemetry, and a physician at bedside until each medication clears assay detection or reaches its protocol-defined threshold. The flood dose is administered only when every threshold is met.

Ibogaine TA booster doses are used to bridge serotonergic and GABAergic tone. Total alkaloid extract — the unrefined Tabernanthe iboga root preparation — at sub-psychoactive doses (50–150 mg BID) is intended to provide receptor-level support during washout without inducing the visionary state. In our clinical experience, patients commonly describe the taper as 'noticeable but tolerable' rather than 'unbearable.' Formal comparative-effectiveness data against home-taper protocols has not yet been published; we report aggregate completion rates on our /outcomes page and contribute to the emerging literature where appropriate.

Read more in our CYP2D6 pharmacogenomics page, the A-Z drug interaction directory, and our cardiac screening protocol.

Onsite Taper Schedule by Medication Class

Class	Examples	Bridge Method	Typical Duration	Flood-Dose Threshold
SSRI	fluoxetine, sertraline, citalopram, escitalopram, paroxetine	TA boosters BID + step-down schedule	7–28 days (longer for fluoxetine)	Below assay LOD + 5 days stable
SNRI	venlafaxine, duloxetine, desvenlafaxine	TA boosters BID + step-down schedule	10–21 days	Below assay LOD + 5 days stable
Benzodiazepine	alprazolam, lorazepam, clonazepam, temazepam	Diazepam crossover + TA boosters BID	10–28 days (use-history dependent)	Diazepam-equivalent < 10 mg + 72 h stable
Z-drug	zolpidem, eszopiclone, zaleplon	Direct discontinuation + TA boosters BID	5–10 days	Full discontinuation + 72 h stable
Stimulant	amphetamine, methylphenidate, lisdexamfetamine	Pre-arrival 48–72 h abstinence	Pre-arrival	Negative urine drug screen on arrival
Long-acting opioid	methadone, oxycodone ER, morphine ER, buprenorphine implant	Pre-arrival physician-supervised bridge to short-acting	≥ 14 days pre-arrival	Stable on short-acting + arrival labs clear

Each schedule is individualised by our medical director based on dose, duration of use, patient tolerance, CYP2D6 phenotype, and concurrent conditions. Durations are typical ranges; outliers exist in both directions and the taper is paused or slowed when symptoms warrant.

The TA Booster

What ibogaine TA actually is — and why sub-psychoactive doses bridge the taper.

Total alkaloid versus HCl. Tabernanthe iboga root bark contains a family of more than a dozen indole alkaloids. The principal constituents are ibogaine, ibogamine, ibogaline, tabernanthine, tabernanthinine, ibogaminol, voacangine, coronaridine, conopharyngine, iboxygaine, ibogainoxine, and noribogaine precursors. The traditional preparation uses the full alkaloid fraction (TA), capturing the receptor-pharmacology of the entire family. Pharmaceutical-grade ibogaine hydrochloride (HCl) isolates a single molecule. Both have therapeutic uses; their dosing profiles, receptor profiles, and clinical roles are distinct. MindScape uses the full TA spectrum for bridging because no single-molecule preparation reproduces the multi-receptor coverage that makes onsite tapering tolerable.

Why TA at sub-psychoactive doses is used for bridging. The 50–150 mg BID window is below the visionary threshold (typically 4–6 mg/kg of pure ibogaine HCl) and is intended to provide serotonergic and GABAergic receptor activity without inducing acute psychoactivity. In our clinical experience, patients at these doses typically describe a mild grounding effect, vital signs and EKG remain within their pre-treatment baseline, and the taper schedule continues without significant interruption. Formal receptor-binding kinetics for the TA mixture remain an active research area; see Glue 2016 and Mash 2018 for the most relevant published pharmacokinetic data.

Why this beats benzodiazepine-cover bridging. Some clinics bridge SSRI tapers with short-course benzodiazepines or sedating antihistamines. Both add their own discontinuation issues, can interact with the upcoming flood dose, and do not address the underlying serotonergic dysregulation that drives discontinuation symptoms. TA bridging works at the receptor level, clears predictably, and is fully compatible with the ibogaine HCl flood dose that follows.

The HCl Flood Dose

The flood dose is administered only after every threshold is met.

Quantitative gating, not clinician discretion alone. Each medication class has an explicit threshold drawn from the published safety literature and our internal admissions data: serum SSRI/SNRI below assay limit of detection plus 5 days symptom-stable; diazepam-equivalent below 10 mg plus 72 hours stable; full Z-drug discontinuation plus 72 hours stable. Independent of medication class, every patient must additionally clear cardiac (QTc < 440 ms male, < 460 ms female), electrolyte (potassium > 4.0 mEq/L, magnesium > 2.0 mg/dL), and hepatic / renal function gates on the morning of dosing.

Telemetry from pre-medication through full noribogaine clearance. Once every threshold is met, the flood dose (8–15 mg/kg ibogaine HCl, individualised by CYP2D6 phenotype, body weight, and treatment indication) is administered under continuous 12-lead telemetry, repeated EKGs at +2 h, +6 h, +12 h, +24 h, and +48 h, and a physician at bedside through the visionary phase. Patients remain on telemetry until plasma noribogaine has cleared the QTc- prolonging window — typically 72–96 hours.

If thresholds are not met, the flood dose is delayed. A small number of patients require an extra 5–7 days. A smaller subset are deemed not suitable for treatment in the current admission and are discharged with a written summary, a referral to their prescribing physician, and an invitation to re-apply once the underlying medical or pharmacological barrier is addressed. Pushing through is not an option.

Cardiac screening protocol · QTc risk calculator · Safety and monitoring overview

Onsite Taper FAQ

What patients and prescribing physicians ask about the onsite protocol.

Three reasons. First, self-directed home tapers are difficult — in our admissions experience a substantial share of patients destabilize, restart their medication, and arrive unable to safely receive ibogaine. Second, abrupt SSRI discontinuation causes well-documented rebound depression, intrusive thoughts, suicidal ideation, and physical symptoms (Fava et al., Psychother Psychosom 2015; Horowitz & Taylor, Lancet Psychiatry 2019) that can derail the treatment journey before it begins. Third, the serotonin-syndrome risk window between SSRI clearance and ibogaine flood dose can be managed by continuous monitoring, electrolyte panels, and bridging — not by blind home washout. Patients arrive on their current prescribed dose and the taper runs under our medical team.

Ibogaine TA — total alkaloid — is the unrefined extract from Tabernanthe iboga root bark, containing ibogaine, ibogamine, ibogaline, tabernanthine, and noribogaine precursors. It is dosed at sub-psychoactive levels (typically 50-150 mg twice daily) during the taper window. At those doses it is intended to support serotonergic and GABAergic tone-bridging without inducing the visionary state; receptor-binding kinetics for the TA mixture remain an active research area (see Glue 2016 and Mash 2018 for the most relevant published pharmacokinetic data). The HCl flood dose (purified ibogaine hydrochloride at 8-15 mg/kg) is the therapeutic 'reset' delivered after the taper is complete and the patient meets protocol-defined safety thresholds.

It depends on the molecule. Short half-life SSRIs like paroxetine and venlafaxine (SNRI) require 10-21 days of supervised step-down with TA bridging. Sertraline and citalopram typically run 7-14 days. Fluoxetine — with its 4-6 day half-life and active metabolite norfluoxetine (16 day half-life) — requires the longest washout, usually 21-28 days. Each schedule is individualized based on dose, duration of use, and patient tolerance. Telemetry runs continuously throughout.

Yes — but only with the right protocol. Patients are first crossed over from short-acting benzodiazepines (alprazolam, lorazepam, clonazepam) to a long-acting benzodiazepine (typically diazepam) for stable plasma coverage. The diazepam dose is then stepped down under continuous physician supervision, with TA boosters bridging GABAergic tone. Vital signs and EKG run continuously. The HCl flood dose is administered only after diazepam reaches a protocol-defined safe threshold — typically below 10 mg diazepam-equivalent. Self-directed benzodiazepine tapering at home carries seizure risk and is never recommended.

The protocol is designed to be tolerable. TA booster bridging is intended to attenuate discontinuation symptoms, and in our internal outcome dataset (available to referring clinicians on request) 98% of admitted SSRI/SNRI/benzodiazepine/Z-drug patients complete the onsite taper and reach flood-dose readiness without restarting their pre-arrival medication. This is a taper-completion metric, not a long-term remission or abstinence rate — long-term durability is a separate question still being studied by Phase 2/3 trials. Formal comparative-effectiveness data against self-directed tapers has not yet been published; our basis is internal admissions outcomes plus the published pharmacokinetic literature (Glue 2016; Mash 2018). If a patient experiences breakthrough symptoms, the taper schedule is paused or slowed — not pushed through. Our medical director makes the final call on flood-dose readiness. Some patients require an extra 5-7 days. A small number are deemed not safe candidates and are referred back to their prescribing physician with a written summary. We do not push patients into a flood dose they are not ready for.

No. Methadone and long-acting opioids (extended-release morphine, oxycodone ER, buprenorphine implants) require a pre-arrival physician-supervised bridge to a short-acting opioid. The reason is pharmacological: the long elimination half-life of methadone (24-36 hours, with substantial inter-individual variation) interacts with ibogaine and noribogaine plasma kinetics in ways that cannot be safely managed in a short admission window. The bridge to a short-acting opioid is typically completed in 14 days minimum, in coordination with the patient's prescribing physician. Once on a short-acting opioid, the patient enters the standard onsite protocol.

Each medication class has a quantitative threshold derived from the published safety literature and our clinical experience. For SSRIs and SNRIs: serum levels below the assay's lower limit of detection, plus 5 days symptom-stable on TA bridging. For benzodiazepines: diazepam-equivalent below 10 mg, plus stable vitals and no withdrawal signs for 72 hours. For Z-drugs (zolpidem, eszopiclone, zaleplon): full discontinuation plus 72 hours symptom-stable. For all classes: baseline QTc below the eligibility threshold, normal potassium and magnesium, normal liver and kidney function. The flood dose is administered only when every threshold is met.

Direct insurance reimbursement for ibogaine treatment is rare in the United States and Mexico because ibogaine is not yet FDA-approved. However, the medical workup components — labs, EKG, cardiology consultation, telemetry — may be reimbursable through some PPO out-of-network plans. We provide itemized superbills upon request. The taper itself is a service we deliver as part of the treatment package. Our finance team works with each patient on payment structure, and we partner with health-care lending platforms for those who qualify.

Medically reviewed by Dr. Arellano, M.D.

Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 900 patients treated.

Last reviewed: May 2026 · See full medical team

Pre-Treatment Consultation

Bring your medication list. We'll build the taper around it.

A free, confidential medication review with our admissions physician — usually within 24 hours. We coordinate directly with your prescribing physician where you want us to.

Book Pre-Treatment Consultation

100% Confidential · No Obligation